QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=B38F0E55D27DDEADFC7082A769BE0553;jsessionid=A80C1084BCAB205CFE92EE04C4D30F96;jsessionid=C681631917234AE5E23D0D8B1F7D0385;jsessionid=CA7BCBB8CFEE74F51344CC67997B0626;jsessionid=7285A5CADB57901518C552379CE75BA9;jsessionid=81AF6B42A54565A95E7BC398981E2B76;jsessionid=3EAE97BE6C7DDDDC8225FAEFF4387F8D (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=B38F0E55D27DDEADFC7082A769BE0553;jsessionid=A80C1084BCAB205CFE92EE04C4D30F96;jsessionid=C681631917234AE5E23D0D8B1F7D0385;jsessionid=CA7BCBB8CFEE74F51344CC67997B0626;jsessionid=7285A5CADB57901518C552379CE75BA9;jsessionid=81AF6B42A54565A95E7BC398981E2B76;jsessionid=3EAE97BE6C7DDDDC8225FAEFF4387F8D